About
On-Off Immunity Treatments
Areas of Focus
Categories
Small Molecule PharmaceuticalBoston & New England
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
4
As Collaborator
0
Total Enrollment
305
By Phase
PHASE1: 3
By Status
COMPLETED: 2ACTIVE_NOT_RECRUITING: 1RECRUITING: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT06982352Lead Sponsor
Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
PHASE1Active, not recruiting
48 participants
Started: Jun 15, 2025 · Completed: Apr 15, 2026
NCT06628206Lead Sponsor
Safety and Pharmacokinetics of LPX-TI641 in Rheumatoid Arthritis and Psoriatic Arthritis
PHASE1Recruiting
48 participants
Started: Dec 15, 2024 · Completed: Jan 15, 2026
NCT05853835Lead Sponsor
First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641
PHASE1Completed
72 participants
Started: Oct 30, 2023 · Completed: Nov 1, 2024
NCT05663853Lead Sponsor
An Observational Biomarker Study in Multiple Sclerosis (MS) Patients
N/ACompleted
137 participants
Started: Mar 28, 2023 · Completed: Apr 30, 2024
Locations (1)
Headquarters
Boston, MA, United States
Map
Loading map...